Ubs Oconnor LLC Revance Therapeutics, Inc. Transaction History

Ubs Oconnor LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.34 - $4.73 $165,313 - $334,160	70,647 Added 27.74%	325,314 $836,000
Q1 2024 May 15, 2024	BUY	$4.65 - $9.31 $674,250 - $1.35 Million	145,000 Added 132.22%	254,667 $1.25 Million
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $121,237 - $233,710	20,867 Added 23.5%	109,667 $963,000
Q3 2023 Nov 14, 2023	BUY	$11.47 - $25.07 $1.02 Million - $2.23 Million	88,800 New	88,800 $1.02 Million
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $1.27 Million - $2.44 Million	-69,061 Reduced 77.36%	20,214 $651,000
Q4 2022 Feb 14, 2023	SELL	$18.32 - $30.66 $218,081 - $364,976	-11,904 Reduced 11.77%	89,275 $0
Q3 2022 Nov 14, 2022	SELL	$14.33 - $28.47 $1.06 Million - $2.11 Million	-74,000 Reduced 42.24%	101,179 $2.73 Billion
Q2 2022 Aug 12, 2022	BUY	$11.52 - $20.4 $981,262 - $1.74 Million	85,179 Added 94.64%	175,179 $2.42 Million
Q1 2022 May 16, 2022	BUY	$12.36 - $20.31 $1.11 Million - $1.83 Million	90,000 New	90,000 $1.76 Million

219

77.6M

2.18M

5.27M

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.